Trial · NCT03880266

A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis

NCT03880266, Phase 2, Completed, Journey Medical Corporation; results first posted 2021-03-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis. Trials, record NCT03880266. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03880266

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
NCT number: NCT03880266
Status: Completed
Phases: Phase 2
Enrollment: 72 participants, actual
Lead sponsor: Journey Medical Corporation
Conditions: Palmar Hyperhidrosis
Interventions: Glycopyrronium cloth, 2.4%, Vehicle
First posted: 2019-03-19
Last updated: 2021-08-25
Results first posted: 2021-03-15
Limitations and caveats: Small sample size

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mean Change From Baseline to Week 2 in Hand Sweating Severity Score	Baseline, Week 2	The Hand Sweat Severity Score is a patient reported outcome, designed to measure the severity of palmar hyperhidrosis \[score on a scale from 0 (better) -10 (worse)\].
Secondary	Percentage of Subjects Who Have a ≥2 Grade Improvement in HDSS (Hyperhidrosis Disease Severity Scale) From Baseline at Week 2	Baseline, Week 2	Hyperhidrosis Disease Severity Scale (HDSS) is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities. 1 (better), 2, 3, 4 (worse)
Secondary	Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 2	Baseline, Week 2	Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; average of the change in the gravimetric measurement of sweat produced at baseline compared with Week 2
Secondary	Mean Percent Change From Baseline in Gravimetrically-measured Sweat Production at Week 2	Baseline, Week 2	Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; calculation of percentage difference in sweat production at week 2 compared to baseline sweat production
Secondary	Percentage of Subjects Who Have at Least a 50% Reduction in Gravimetrically-measured Sweat Production From Baseline at Week 2	Baseline, Week 2	Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; confidence interval represents difference between vehicle and active group

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Mean Change From Baseline to Week 2 in Hand Sweating Severity Score	Baseline, Week 2	Intent to Treat Population	score on a scale	MEAN
SECONDARY	Percentage of Subjects Who Have a ≥2 Grade Improvement in HDSS (Hyperhidrosis Disease Severity Scale) From Baseline at Week 2	Baseline, Week 2	Intent to Treat Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 2	Baseline, Week 2	Intent to Treat Population	mg	MEAN
SECONDARY	Mean Percent Change From Baseline in Gravimetrically-measured Sweat Production at Week 2	Baseline, Week 2	Intent to Treat Population	Percent change	MEAN
SECONDARY	Percentage of Subjects Who Have at Least a 50% Reduction in Gravimetrically-measured Sweat Production From Baseline at Week 2	Baseline, Week 2	Intent to Treat Population	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group40

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Mean Change From Baseline to Week 2 in Hand Sweating Severity Score	Group 1 Active	-2.14	Standard Deviation 2.199	score on a scale
Mean Change From Baseline to Week 2 in Hand Sweating Severity Score	Group 1 Vehicle	-0.56	Standard Deviation 0.730	score on a scale
Mean Change From Baseline to Week 2 in Hand Sweating Severity Score	Group 2 Active	-1.64	Standard Deviation 1.410	score on a scale
Mean Change From Baseline to Week 2 in Hand Sweating Severity Score	Group 2 Vehicle	-3.03	Standard Deviation 2.161	score on a scale
Mean Change From Baseline to Week 2 in Hand Sweating Severity Score	Group 3 Active	-2.53	Standard Deviation 2.223	score on a scale
Mean Change From Baseline to Week 2 in Hand Sweating Severity Score	Group 3 Vehicle	-2.20	Standard Deviation 1.084	score on a scale
Mean Change From Baseline to Week 2 in Hand Sweating Severity Score	Group 4 Active	-1.30	Standard Deviation 2.062	score on a scale
Mean Change From Baseline to Week 2 in Hand Sweating Severity Score	Group 4 Vehicle	-1.34	Standard Deviation 1.909	score on a scale
Percentage of Subjects Who Have a ≥2 Grade Improvement in HDSS (Hyperhidrosis Disease Severity Scale) From Baseline at Week 2	Group 1 Active	3		Participants
Percentage of Subjects Who Have a ≥2 Grade Improvement in HDSS (Hyperhidrosis Disease Severity Scale) From Baseline at Week 2	Group 1 Vehicle	0		Participants

1 to 10 of 40Source ClinicalTrials.gov

See all 40 results by group

Participant flow24

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Group 1 Active	12
Overall Study	STARTED	Group 1 Vehicle	6
Overall Study	STARTED	Group 2 Active	12
Overall Study	STARTED	Group 2 Vehicle	4
Overall Study	STARTED	Group 3 Active	12
Overall Study	STARTED	Group 3 Vehicle	6
Overall Study	STARTED	Group 4 Active	13
Overall Study	STARTED	Group 4 Vehicle	7
Overall Study	COMPLETED	Group 1 Active	12
Overall Study	COMPLETED	Group 1 Vehicle	5

1 to 10 of 24Source ClinicalTrials.gov

See all 24 participant flow

Adverse events136

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Dry Mouth	Gastrointestinal disorders	Group 1 Active	1	12	1
other	Dry Mouth	Gastrointestinal disorders	Group 1 Vehicle	1	6	1
other	Dry Mouth	Gastrointestinal disorders	Group 2 Active	2	12	2
other	Dry Mouth	Gastrointestinal disorders	Group 2 Vehicle	0	4	0
other	Dry Mouth	Gastrointestinal disorders	Group 3 Active	0	12	0
other	Dry Mouth	Gastrointestinal disorders	Group 3 Vehicle	0	6	0
other	Dry Mouth	Gastrointestinal disorders	Group 4 Active	0	13	0
other	Dry Mouth	Gastrointestinal disorders	Group 4 Vehicle	0	7	0
other	Abdominal pain upper	Gastrointestinal disorders	Group 1 Active	0	12	0
other	Abdominal pain upper	Gastrointestinal disorders	Group 1 Vehicle	0	6	0

1 to 10 of 136Source ClinicalTrials.gov

See all 136 adverse events

Adverse event totals24

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Group 1 Active	0	12
Total, all-cause mortality	Group 1 Vehicle	0	6
Total, all-cause mortality	Group 2 Active	0	12
Total, all-cause mortality	Group 2 Vehicle	0	4
Total, all-cause mortality	Group 3 Active	0	12
Total, all-cause mortality	Group 3 Vehicle	0	6
Total, all-cause mortality	Group 4 Active	0	13
Total, all-cause mortality	Group 4 Vehicle	0	7
Total, other adverse events	Group 1 Active	5	12
Total, other adverse events	Group 1 Vehicle	2	6

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03880266

GET https://conductscience.org/api/trials/v1/NCT03880266/results?page=2

API reference For AI assistants